EVM16

Phase 1Biologic

PPeking University

EVM16 is one of 2 biologic programs targeting Advanced or Recurrent Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced or Recurrent Solid TumorsRecruiting

Advanced or Recurrent Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Advanced or Recurrent Solid Tumors

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 1

1 2

EVM16

PPeking University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Advanced or Recurrent Solid Tumors

NCT06541639

Clinical

Trials by Indication[1]

Advanced or Recurrent Solid Tumors1 trial

A Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, and Initial Efficacy of EVM16 Injection as a Single and Combination With Tislelizumab in Subjects With Advanced or Recurrent Solid Tumors

Recruiting·PPeking University·Phase 1·NCT06541639·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EVM16. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EVM16 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EVM16. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: PPeking University

EVM16

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Advanced or Recurrent Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News